News

September 21, 2020September 21, 2020

FDA Acts to Speed Toripalimab as Potential Nasopharyngeal Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) has designated toripalimab (JS001) a breakthrough therapy as a potential treatment of nasopharyngeal carcinoma (NPC), one of the most common cancers in China and one lacking treatment ... Read more

September 18, 2020September 18, 2020

EMA to Review Opdivo-Yervoy Combo for Untreated, Inoperable Mesothelioma

News

The European Medicines Agency has agreed to review Bristol Myers Squibb’s application requesting approval for the dual immunotherapy regimen Opdivo (nivolumab) and Yervoy (ipilimumab) for untreated, inoperable malignant pleural mesothelioma (MPM). This decision ... Read more

September 14, 2020September 14, 2020

Post-surgery Opdivo Shows Benefits for Esophageal, GEJ Cancer Patients in Ongoing Trial

News

Opdivo (nivolumab) significantly prolongs the time patients with resected esophageal or gastroesophageal junction (GEJ) cancer live without signs of disease after receiving chemoradiation therapy followed by cancer removal surgery, interim ... Read more

September 9, 2020September 9, 2020

Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trial

News

Tessa Therapeutics’ investigational CD30 CAR-T cell therapy is safe and leads to a high rate of strong and sustained responses in people with relapsed or treatment-resistant Hodgkin’s lymphoma, according to ... Read more

September 4, 2020September 4, 2020

FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for Liver Cancer

News

The U.S. Food and Drug Administration (FDA) has issued a complete response letter stating that it will not approve the combination of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) as a first-line treatment for people ... Read more

September 2, 2020September 2, 2020

Imfinzi Approved in EU for Extensive-stage Small Cell Lung Cancer

News

The European Commission has approved a combination of Imfinzi (durvalumab) plus standard chemotherapy as a first-line treatment for people with extensive-stage small cell lung cancer (SCLC). Findings from the CASPIAN ... Read more

August 31, 2020August 31, 2020

Imfinzi as Once Monthly NSCLC, Bladder Cancer Treatment Under FDA Review

News

The U.S. Food and Drug Administration (FDA) has accepted and given priority review to AstraZeneca‘s application requesting a new dosing regimen for Imfinzi (durvalumab) to treat certain non-small cell lung cancer (NSCLC) and bladder ... Read more

August 26, 2020August 26, 2020

Novocure, MSD Team Up to Test TTFields-Keytruda Combo in Lung Cancer

News

An upcoming Phase 2 clinical trial is set to evaluate Novocure‘s Tumor Treating Fields, known as TTFields, in combination with Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer ... Read more

August 17, 2020September 23, 2020

Health Canada Approves Opdivo-Yervoy-Chemo Combo for Advanced NSCLC

News

Note: This story was updated Sept. 23, 2020, to note that the triple combination reduced the risk of death by 34%, not 37%. Health Canada has approved a combination therapy ... Read more

August 12, 2020August 12, 2020

Opdivo-Yervoy Combo Prolongs Survival of Patients With Inoperable Mesothelioma, Phase 3 Trial Shows

News

A dual immunotherapy regimen of Opdivo (nivolumab) and Yervoy (ipilimumab) can prolong the survival of patients with untreated, inoperable malignant pleural mesothelioma (MPM), according to data from a Phase 3 clinical ... Read more